

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				INT'L FILING NO.		PCT/GB2005/001333	
				INT'L FILING DATE		April 6, 2005	
				APPLICANT		Heightman et al.	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PB60825USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
/B.C./	1.	4,210,749	7/1/1980	Shetty			
/B.C./	2.	5,364,791	11/15/1994	Vegeto et al.			
/B.C./	3.	5,874,534	2/23/1999	Vegeto et al.			
/B.C./	4.	5,935,934	8/10/1999	Vegeto et al.			
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
/B.C./	5.	WO96/05194	2/22/1996	PCT			abstract only
/B.C./	6.	WO00/21951	4/20/2000	PCT			
** /B.C./	7.	WO00/23437	4/27/2000	PCT			abstract only
/B.C./	8.	WO01/03680	1/18/2001	PCT			
** /B.C./	9.	WO01/87834	11/22/2001	PCT			abstract only
** /B.C./	10.	WO02/02530	1/10/2002	PCT			abstract only
** /B.C./	11.	WO02/14513	2/21/2002	PCT			abstract only
** /B.C./	12.	WO02/15934	2/28/2002	PCT			abstract only
/B.C./	13.	WO02/040471	5/23/2002	PCT			
/B.C./	14.	WO03/090751	11/6/2003	PCT			
/B.C./	15.	WO04/018432	3/4/2004	PCT			
/B.C./	16.	WO04/056369	7/8/2004	PCT			
/B.C./	17.	WO04/026305	4/1/2004	PCT			
/B.C./	18.	WO04/035544	4/29/2004	PCT			
/B.C./	19.	WO05/14479	2/17/2005	PCT			
/B.C./	20.	WO05/039591	5/6/2005	PCT			
/B.C./	21.	1268243	3/22/1972	GB			
** /B.C./	22.	2207430	8/23/1973	DE			no
** /B.C./	23.	2171879	9/28/1973	FR			no
** /B.C./	24.	2001226269	8/21/2001	JP			no
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
/B.C./	25.	AUSTIN et al., Novel 2,3,4,5-Tetrahydro-1H-3-benzazepines with High Affinity and Selectivity for the Dopamine D ₃ Receptor, Bioorg. & Med. Chem. Ltrs. 10 :2553-2555 (2000).					
/B.C./	26.	SMIT et al., Regulation of the human histamine H1 receptor stably expressed in Chinese hamster ovary cells, Br. J. Pharmacol. 117 (6):1071-1080 (1996).					
/B.C./	27.	GIOVANNINI et al., "Effects of histamine H ₃ receptor agonist and antagonists on cognitive performance and scopolamine-induced amnesia," Behavioral Brain Res. 104 :147-155 (1999).					
/B.C./	28.	LEURS et al., "Therapeutic potential of histamine H ₃ receptor agonists and antagonists," TiPS 19 :177-183 (May 1998).					
/B.C./	29.	LOVENBERG et al., "Cloning and Functional Expression of the Human Histamine H ₃ Receptor," Molecular Pharmacology 55 :1101-1107 (1999).					
/B.C./	30.	ONODERA and WATANABE, "Histamine H ₃ Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).					
/B.C./	31.	SCHLICKER et al., Modulation of Neurotransmitter Release via histamine H ₃ heteroreceptors, Fund. Clin. Pharmacol. 8 :128-137 (1994).					
/B.C./	32.	SULLIVAN et al., Calcium Signaling Protocols, (In: Lambert DG (ed.) New Jersey; Humana Press, 1999, 125-134.					
/B.C./	33.	VILLALOBOS et al., Novel Benzisoxazole Derivatives as Potent and Selective Inhibitors of Acetylcholinesterase, J. Med. Chem. 37 :2721-2734 (1994).					
EXAMINER /Brenda Coleman/					DATE CONSIDERED 09/15/2008		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

** Structures only